These reports are available to the public on the MAUDE database which is a repository of incidents that were not experienced by approved medical devices during their premarket testing. In addition to such reports that are submitted to the FDA during pre-market approval, manufacturers must also submit adverse events that occur during actual use of the device. It is mandatory for medical device manufacturers to submit safety and effectiveness data to the FDA, disclosing adverse effects on patients during clinical trials, and submit a summary of the same. In the event of serious injury or death on account of malfunctioning of devices, it is mandatory for manufacturers and importers to submit to the USFDA, reports containing information on such events. These issues can compromise the safe use of infusion pumps and lead to over or under-infusion, missed treatments or delayed therapy. More recently, smart infusion pumps have been designed to alert the user when there is a risk of improper drug infusion or when the user sets the pump’s parameters outside of specified safety limits. Many infusion pumps are equipped with safety features such as alarms or other operator alerts that are intended to activate in the event of a problem. Infusion pumps are frequently used to administer critical fluids including high-risk medications, and hence, pump failures can have significant implications on patient safety. For example, providing PCA data into patient monitoring systems could be used to manage the risk of respiratory depression from the over use of opioids.”įor more information on the CADD-Solis ambulatory infusion pump range contact Glen Johnson, NordUK Marketing Manager at Smiths Medical, on 01233 722 100, email or visit References:ġ Wireless communication at launch only available for English language pumpsĢ Model 2100 pumps manufactured before 2011 (Serial Numbers < 10012365) cannot be upgraded to v4.Infusion pumps are used to treat diseases and disorders that require regular pharmacological intervention such as cancer, diabetes, and vascular, neurological, and metabolic disorders. Wireless bi-directional communication sets the foundation for integrating pain management data directly into the patient records in the hospital’s Electronic Medical Records (EMR), saving clinician time charting and increasing documentation accuracy. Jeff Hohn, General Manager & Vice President, Infusion Systems, at Smiths Medical, said: “The new CADD-Solis system is a continuation of Smiths Medical’s commitment to advancing patient care and helping to improve outcomes through leading-edge technology. Turning off wireless communications or the lack of wireless access does not impact pump delivery or data retention.
#Cadd pain pump upgrade
Ĭustomers can continue to use previous versions or choose to upgrade any CADD-Solis model 2110 pump to CADD-Solis v4.1 software using SureLink ® remote support software, while maintaining their existing drug library. Wireless two-way communication with the PharmGuard ® Server software to help increase efficiencies, reduce costs, and improve patient outcomes.The addition of profiles to categorise drug protocols or represent care areas.
#Cadd pain pump full
The CADD-Solis v4.1 pump is UL-marked and has full compliance with the latest product standards, including IEC-60601-1 Edition 3.1.
Smiths Medical, a global medical device manufacturer, has released the CADD ®-Solis ambulatory infusion pump version 4.1 that sets the foundation for wireless communication globally.
0 kommentar(er)
